HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders

HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders

BackgroundHematopoietic progenitor kinase 1 (HPK1) is a member of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family. It has been reported that HPK1 negatively regulates the activation of T cells. Several compounds have been developed and tested in clinical trials to target HPK...

Full description

Saved in:
Bibliographic Details
Main Authors: Qin Wang, Xinyi Zhu, Jing Li, Sanjia Xu, Ali Wang, Xinwen Zhang, Xingxing Wang, Xiaopeng Cai, Haimei Xing, Ye Liu, Xuesong Liu, Zhiwei Wang, Lai Wang, Xi Yuan
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
hematopoietic progenitor kinase 1
kinase
non-catalytic function
T cell receptor signaling
degrader
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1449106/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items